Please login to the form below
PD-L1 inhibitors
This page shows the latest PD-L1 inhibitors news and features for those working in and with pharma, biotech and healthcare.
Gilead makes a play for novel cancer drug with Tizona deal
anti-PD-1/L1 therapies and deepen responses in tumours that are sensitive to these treatments. ... Gilead, however, is looking past PD-1/L1 inhibitors to the next class of transformative treatments, with its play for Tizona just the latest in a string of
Latest news
-
Tecentriq misses the mark in advanced ovarian cancer
Tecentriq is part of a new class of immunotherapy treatments, also known as PD-1/L1 inhibitors, that have transformed the market over the last few years. ... The FDA approval for Imfinzi makes AZ’s drug the first PD-1/PD-L1 inhibitor to challenge
-
Merck KGaA, Pfizer’s Bavencio stumbles in head and neck cancer
PD-L1 inhibitor – this time stumbling in head and neck cancer. ... 1/PD-L1 inhibitors spilling across a number of cancer types and ramping up the competition.
-
AstraZeneca’s Imfinzi fails first-line bladder cancer test
PD-L1 inhibitor Imfinzi (durvalumab) – given on its own and in combination with experimental CTLA4 inhibitor tremelimumab – wasn’t able to improve overall survival in patients with advanced (stage IV) bladder ... In the trial, Imfinzi monotherapy
-
Immutep spikes on trial of its LAG-3 drug with Keytruda
The PD-1/PD-L1 checkpoint inhibitors that hit the market in 2015 have already transformed the standard of care for some cancers, but there is still a sizeable patient population ... so “the results showing an almost 50% [response] across all patients
-
Innate Pharma and AstraZeneca take monalizumab into phase 3
AZ has vested interested in Innate’s candidate because of data which shows that it can improve the effectiveness of PD-1/PD-L1 inhibitors like AZ’s own Imfinzi (durvalumab).
More from news
Approximately 1 fully matching, plus 43 partially matching documents found.
Latest Intelligence
-
Immuno-oncology in 2019: the rapid evolution continues
In addition to the PD-1 inhibitors Keytruda and Opdivo, there are four PD-L1 inhibitors: Roche’s Tecentriq, AstraZeneca’s Imfinzi, Pfizer and Merck’s Bavencio and Sanofi and ... PD-1/PD-L1 inhibitors: Keytruda is King, but the market is developing
-
The good, the bad and the ugly
Companies are looking to pair their PD-1/PD-L1 checkpoint inhibitors with a variety of other agents to stimulate a more robust anticancer immune response,” says Xuan.
-
European venture funding for the life science sector
is likely to accelerate interest - the sheer number of combination therapies and PD-1/PD-L1 inhibitors could result in a commoditisation of this area that could threaten returns for venture
-
Medius Deal Watch table for March 2015
170. Checkpoint Therapeutics / TG. Licence and collaboration. Human anti-PD-L1 and anti-GITR antibody preclinical programmes for haematological cancers. ... CAR-T and checkpoint inhibitors PD-1 and PD-L1. 110. Transtech / Calithera.
-
Deal Watch table for November 2014
PD-L1 and PD-1 CP inhibitors. Co-development and co-marketing alliance. 2, 850. ... FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor).
More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Manager Healthcare / Pharmaceutical Sector
-
Negotiable Salary
- Sales Director, Healthcare communications agency, London/ SE UK
-
Six figure salary
-
Medical Editor
-
Competitive
-
Healthcare Lead Copywriter
-
Competitive
-
Healthcare Senior Account Manager
-
Competitive
-
Healthcare Account Director
-
Competitive
- Sanofi, GSK delay COVID-19 vaccine trial after underwhelming results in elderly participants
- PHE study finds people who have had COVID-19 can still transmit the virus
- Bayer’s finerenone scores FDA priority review for chronic kidney disease
- UK pharmacies to begin administering COVID-19 vaccinations
- J&J could launch its single-dose COVID-19 vaccine in March
- AZ seeks EU approval for its Oxford University-partnered COVID-19 vaccine
- Future-Proofing Healthcare and Medicine
- AI in Computer Vision Technology and the Impact on Healthcare
- Lateral flow tests detect ‘most infectious’ COVID-19 cases, Oxford researchers find
- Trial failure for bintrafusp alfa casts doubt on GSK/Merck KGaA’s cancer alliance
- Pfizer/BioNTech's COVID-19 vaccine found to be effective against UK virus variant
- BMS aims for US approval of Opdivo combo in stomach cancer
PMHub
KVA Digital
KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...
Latest intelligence
- The pandemic preparedness paradox
- Why our efficient ‘just in time’ mentality must be replaced with a resilient ‘just in case’ activity...
- Sourcing R&D innovation: why pharma companies need to evolve their business models
- Recent years have seen a significant shift in drug development to specialty areas...
- 2020 - a year to remember or forget?
- 2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Quick links
Infographics
